Company Overview and News

 
Weibo - Bigger Than Twitter

2018-04-17 seekingalpha
Sina Weibo is a Chinese microblogging website and one of the most popular social media websites in China. Sina Corp. spun off Weibo in 2014 but retains a 46% stake in the company. Alibaba (another EMQQ holding) is Weibo’s second largest shareholder with a 32% stake in the company. Weibo is the Chinese word for microblog.
Upvote Downvote

 
How To Profit From Chinese Companies' Going-Home Frenzy

2018-04-10 seekingalpha
Among big caps, Alibaba is likely to be the first one to trade CDRs of its shares in China.
Upvote Downvote

 
If the FAANGs have got you down, it’s time to win with the WNSSS stocks - MarketWatch

2018-03-31 marketwatch
Weibo, Nvidia, ServiceNow, Square and Shopify could dominate in the future, just as the FAANGs have in the past
Upvote Downvote

 
China tech stocks gutted ahead of tariff announcement - MarketWatch

2018-03-22 marketwatch
Losses in Chinese tech stocks outpaced their U.S. counterparts Thursday leading up to the announcement of tariffs against China.
Upvote Downvote

 
Bringing tech home

2018-03-10 thestar.com.my
Rules impediment: A file picture shows people walking past an International Women’s Day advertisement by Tmall, Alibaba’s e-commerce platform, at a subway station in Beijing. China securities rules don’t permit classes of stock that give greater voting rights to founders and leaders, an impediment for Alibaba Group’s Jack Ma. — Reuters
Upvote Downvote

1
Weibo Stock: The Sky Is the Limit for Weibo Corp (ADR) | InvestorPlace

2018-03-09 investorplace
Weibo Corp (ADR) (NASDAQ:WB) isn’t always the first company that Americans think of when they think of the online juggernauts in China. But they should.
Upvote Downvote

 
China Looks to Claw Back $1.4 Trillion in Lost Tech Listings - Bloomberg

2018-03-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Zacks Market Edge Highlights: Vale, Sina, Tencent, Facebook and Twitter

2018-03-08 zacks
Chicago, IL – March 8, 2018 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: (https://www.zacks.com/stock/news/294812/where-to-invest-to-ride-out-the-stock-market-volatility)
Upvote Downvote

 
Where to Invest to Ride out the Stock Market Volatility

2018-03-07 zacks
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
Upvote Downvote

 
Nasdaq ties up with Sina to offer US stock market data to China’s growing pool of investors

2018-03-06 scmp
The US exchange will license two of its products offering data on individual stocks as well as indices and exchange-traded funds
Upvote Downvote

 
SINA / Sina Corp. / MACQUARIE GROUP LTD - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     SINA Corp (Name of Issuer) Common Shares (Title of Class of Securities) G81477104 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d)   * The remainder of
Upvote Downvote

 
SINA / Sina Corp. / MACQUARIE GROUP LTD - SC 13G/A (Passive Investment)

2018-02-15 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*     SINA Corp (Name of Issuer) Common Shares (Title of Class of Securities) G81477104 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d)   * The remainder of
Upvote Downvote

 
Emerging-market ETFs on track for biggest weekly gain since 2016 - MarketWatch

2018-02-15 marketwatch
Exchange-traded funds that track emerging-market equities rallied on Thursday, extending their recent gains and putting them on track for their best weekly performance in more than a year. The iShares MSCI Emerging Markets ETF EEM, +1.74% rose 1.6% on Thursday, putting it on track for its fifth straight daily gain and bringing its weekly advance to 6.5%. That represents its biggest one-week percentage rise since March 2016.
Upvote Downvote

 
SINA Q4 Earnings In Line With Estimates, Revenues Surpass

2018-02-14 zacks
SINA Corporation’s (SINA - Free Report) fourth-quarter 2017 non-GAAP earnings of 79 cents per share surged 25.4% from the year-ago quarter and matched the Zacks Consensus Estimate. Net revenues grew 61% to $503.7 million and beat the Zacks Consensus Estimate of $487 million. Non-GAAP net revenues increased 61% to $501.1 million. Quarter Details Advertising revenues surged 58% year over year to $424.
Upvote Downvote

1
Blowout Earnings Send Weibo Corp Stock Soaring but Watch for Risks | InvestorPlace

2018-02-14 investorplace
Weibo Corp (ADR) (NASDAQ:WB) is soaring on Tuesday morning, with WB stock up more than 8% as of this writing. The catalyst is a strong Q4 report, in which revenue and earnings both came in well ahead of Street expectations.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: G81477104